Mutants Affecting Thymidine Metabolism in Neurospora crassa by Williams, Larry G. & Mitchell, H. K.
JOURNAL OF BACTERIOLOGY, Oct. 1969, p. 383-389
Copyright © 1969 American Society for Microbiology
Mutants Affecting Thymidine Metabolism in
Neurospora crassa
LARRY G. WILLIAMS' AND H. K. MITCHELL
Division of Biology, California Institute of Technology, Pasadena, California 91109
Received for publication 8 July 1969
When '4C-thymidine labeled only in the ring is administered to Neurospora crassa,
the majority of the recovered label is found in the ribonucleic acid (RNA). Three
mutants were isolated in which different steps are blocked in the pathway that con-
verts the pyrimidine ring of thymidine to an RNA precursor. Evidence from genetic,
nutritional, and accumulation studies with the three mutants shows the pathway
to proceed as follows: thymidine -- thymine -- 5-hydroxymethyluracil 5-formyl-
uracil -> uracil -k uridylic acid. A mutant strain in which the thymidine to thymine
conversion is blocked is unable to metabolize thymidine appreciably by any route,
including entry into nucleic acids. This suggests that Neurospora lacks a thymidine
phosphorylating enzyme. A second mutation blocks the pathway at the 5-hydroxy-
methyluracil to 5-formyluracil step, whereas a third prevents utilization of uracil
and all compounds preceding it in the pathway. The mutant isolation procedures
yielded three other classes of mutations which are proposed to be affecting, respec-
tively, regulation of the thymidine degradative pathway, transport of pyrimidine
free bases, and transport of pyrimidine nucleosides.
The use of radioactively labeled thymidine as a
means of specifically labeling the deoxyribonucleic
acid (DNA) of an organism requires that the
organism possess a thymidine phosphorylating
enzyme and that it lack enzymes which rapidly
degrade thymidine. The latter of these conditions
is not met in some organisms, because in auto-
radiographic studies uniformly labeled 'H-thymi-
dine fails to label specifically theDNA of Acetabu-
laria (6), Spirogyra (18, 20), Paramecium aurelia
(5), and Neurospora crassa (3). In fact, a majority
of the label is incorporated into the ribonucleic
acid (RNA) fraction.
A metabolic pathway by which thymidine could
be converted to RNA precursors was demon-
strated in N. crassa (12-14). By administer-
ing 14C-thymidine labeled at various positions in
the pyrimidine ring, Fink and Fink showed a
pattem of labeling in the nucleic acid fraction
similar to that obtained with labeled uridine, that
is, 8 to 10 times more label in RNA than in DNA.
When thymidine 8H-methyl was administered, no
label was found in either the RNA or DNA frac-
tion. These data, supplemented by identification
of some of the early products of thymidine degra-
dation, including 5-hydroxymethyluracil (5-
HMU), indicated a conversion of thymidine to
I Present address: Department of Botany, University of Michi-
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uracil through the stepwise oxidation and ulti-
mate elimination of the methyl group of thymine.
A simplified diagram of pyrimidine metabolism,
including the thymidine to uracil pathway, is
shown in Fig. 1.
The purpose of the experiments reported here
was to isolate mutants of the pathway by which
thymidine is converted to an RNA precursor.
With these mutants, the steps involved in the
salvage pathway were better defined. Finally, mu-
tants so blocked were tested to determine whether
they could incorporate thymidine specifically into
DNA.
MATERIALS AND METHODS
Strains. Wild-type strains 4A and 25a, three py-
rimidine mutants, pyr-3 (37301a), pyr-J (H-263a),
and pyr-4 (36601a), and one purine mutant (ad-6)
were used. The mutants were kindly provided by
Mary B. Mitchell from the Neurospora stocks of
the California Institute of Technology Division of
Biology.
Media and chemicals. All mutant stocks were
maintained on the complete medium of Horowitz
(16). The medium used for all mutant isolation pro-
cedures (with one exception), growth tests, and crosses
was that of Westergaard and Mitchell (21), with
appropriate modifications of carbon source, agar
content, and pyrimidine supplement. The Wester;
gaard-Mitchell medium, which lacks NH4+ nitrogen,
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was chosen for these studies because it permits effi-
cient utilization (as pyrimidine sources) of the inter-
mediates of the thymidine degradative pathway. The
normal carbon source of 2% sucrose was replaced
by 0.2% sucrose and 1.5% sorbose when colonial
growth was desired. Radioactive 2-14C-thymidine (30
mc/mmole) and 2-14C-thymine (45 mc/mmole)
were purchased from the New England Nuclear
Corp., Boston, Mass. Most nonlabeled pyrimidines
were purchased from commercial sources. However,
5-formyluracil was synthesized by the method of
Cline et al. (9), and 5-fluorodeoxyuridine was ob-
tained from R. Duschinsky of Hoffman-La Roche,
Inc., Nutly, N.J.
Mutagenesis and filtration enrichment. A 10-ml
conidial suspension (4 X 106/ml) of a pyr mutant
was added to a petri dish (100 by 15 mm) and placed
7.5 cm beneath an ultraviolet (UV) germicidal lamp
for from 30 sec to 2 min. The highest yield of mu-
tants was obtained with a UV exposure giving 50%
conidial survival.
For the selection of some mutants, a filtration
enrichment procedure was employed (22). A 2.5-ml
portion of the irradiated conidial suspension was
inoculated into a 250-ml Erlenmeyer flask containing
50 ml of medium, supplemented with 2 to 3 jamoles
of the pyrimidine for which nutritional mutants were
desired. The conidia were kept in suspension on a
rotary shaker, with periodic filtration through a
layer of glass wool whenever mycelia became visible.
Seven to eight filtrations over a period of 48 to 72 hr
at 25 C gave optimal recovery of mutants among
surviving conidia.
Immediately after UV irradiation or after the
filtration enrichment procedure, 0.1 to 1.0 ml of
conidial suspension was spread onto sorbose plates
with 0.5 to 2.0 umoles of pyrimidine supplement. At
25 C, colonies continued to appear on the plates
from 3 to 7 days after inoculation. The sorbose plates
were scanned each day, and newly appearing colonies
were transferred from the agar to complete medium
slants.
Mutant selection. In selection of mutants affecting
the conversion of thymidine to an RNA precursor,
cognizance must be taken of two factors. First,
mutations affecting this pathway would not normally
be detected since Neurospora can synthesize sufficient
pyrimidine de novo for growth. However, by em-
ploying a pyr mutant (Fig. 1) as a parent strain
the organism can be made dependent on pyrimidine
salvage pathways. Second, pyr mutant conidia will
not grow when early intermediates of the thymidine
degradative pathway, thymidine, thymine, 5-HMU,
and 5-formyluracil, are the sole pyrimidine sources,
even though these compounds are utilized if growth
is initiated by the addition of uridine or cytidine.
Levels of uridine as low as 0.1 umole/25 ml of liquid
medium will permit the utilization of some thymidine
(0.1 to 0.2 ;mole) as a pyrimidine source. Five differ-
ent methods were devised to select for mutations
affecting the thymidine to RNA precursor pathway.
(i) The first selection method was based on the
fact that conidial colonies of pyr-4 on sorbose plates
containing limiting uridine plus excess thymidine
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FIG. 1. Schematic diagram ofpyrimidine metab-
olism in N. crassa and the proposed sites ofaction of
mutations affecting pyrimidine salvage pathways.
(0.008 and 0.08 mm, respectively) were larger than
if thymidine were lacking. Irradiated pyr-4 conidia
were inoculated onto the double-supplemented plates
and were incubated until a majority of the colonies
had reached a size that indicated they were using
thymidine. At this point the smallest colonies were
removed and tested for their ability to use thymidine
as a pyrimidine source.
(ii) The second procedure designed to yield mutants
able to use thymidine as a sole pyrimidine source
consisted of inoculating about 4 X 106 irradiated
pyr-4 conidia onto sorbose plates containing only
thymidine as a pyrimidine source. The few resulting
colonies were isolated.
(iii) The third selection method employed the
filtration-enrichment procedure. It was especially
useful when derivatives able to use thymidine, thy-
mine, and 5-HMU as sole pyrimidine sources became
available by the second method. Irradiated conidia
were incubated in filtration-enrichment medium con-
taining thymidine, and the surviving conidia, pre-
sumably enriched in mutant conidia unable to use
thymidine, were spread onto sorbose plates supple-
mented with uridine. Resulting colonies were tested
to determine whether they carried a mutation which
blocked a step in the thymidine to RNA precursor
pathway.
(iv) The fourth method is a variation of the above
filtration-enrichment procedure, in which mutants
which could not utilize uracil were selected specifi-
cally. UV-irradiated pyr-l conidia were incubated in
uracil-supplemented enrichment medium, and sur-
viving conidia were inoculated onto uridine-supple-
mented sorbose plates.
(v) Finally, the filtration-enrichment procedure
was used to select for mutants which could not utilize
uridine but which still could use uracil as a pyrimidine
source. Irradiated pyr-l conidia were incubated in
Fries filtration medium (4) supplemented with uridine.
Uracil is used very poorly on Fries medium, and the
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use of this medium protected against the possibility
that mutants which could not utilize uridine as such
might be lost because they possessed an adaptive
system to convert uridine to uracil. Conidia surviving
the filtration step were inoculated onto sorbose
plates of Westergaard-Mitchell medium supple-
mented with uracil.
Growth conditions. Growth responses of mutant
strains to various pyrimnidines were measured in
terms of the dry weight of mycelia. The mold was
cultured for 5 to 6 days at 25 C in 25 ml of medium
in 125-ml Erlenmeyer flasks. The first 2 days of growth
were stationary, after which the flasks were placed
on a shaker for the remainder of the growth period.
The mycelial pads were removed, dried overnight
at 70 C, and weighed. Under these conditions, dry
weights were reproducible to 10%.
RNA and DNA extraction. An adaptation of the
perchloric acid extraction procedure of Ogur and
Rosen (19) was used for extraction of RNA and DNA
components. Growth medium was removed from
the fresh mycelia by rinsing with water and by gentle
suction in a Buchner funnel. Alcohol- and ether-
soluble substances were extracted by three changes
each of absolute ethyl alcohol, a 1:1 (v/v) mixture
of absolute ethyl alcohol and ethyl ether, and ether.
Approximately 20 parts of solvent per gram of mold
(wet weight) was used in each solvent change. The
ether-dry pad was then ground in cold 1.0 M HClO4
(1.0 ml per 50 mg of mycelial dry weight) and allowed
to stand for 12 hr at 0 C. The mixture was then cen-
trifuged and the supernatant fluid was removed;
the residue was extracted with cold HC1O4 in the same
way five more times. The cold HClO4 extract con-
tained essentially all of the RNA in a partially de-
graded form. The residue from the RNA extraction
was extracted three times at 75 C for 15 min with
1.0-ml portions of 1.0 M HClO4. This treatment par-
tially degraded and made soluble all of the DNA.
The reliability both of the extraction procedure in
separating RNA and DNA and of the calculation of
nucleic acid concentration from the UV absorption
(260 nm) of the extracts was confirmed by RNA
and DNA concentration measurements based on
pentose (Bial's reagent; 19) and deoxypentose (di-
phenylamine reagent; 7) content of the extracts.
Radioactive labeling procedure. The HClO4 RNA
and DNA extracts were neutralized at 0 C with KOH,
and the precipitated KClO4 was discarded. In 14C
labeling experiments, samples (0.01 to 0.05 ml) of
the growth medium at the start, used growth medium,
alcohol extracts, ether extracts, and neutralized
HClO4 extracts were applied to aluminum planchets,
dried, and counted on a gas flow counter (Nuclear-
Chicago Corp., Des Plaines, Ill.).
Chromatography. Nonutilized pyrimidine supple-
ments or pyrimidines excreted into the medium
during growth were identified by their elution pattern
from a Dowex-50 ion-exchange column, their charac-
teristic UV absorption spectra, and their RF in com-
parison with known pyrimidines as determined by
paper chromatography. Uridine, 5-HMU, thymidine,
uracil, and thymine can be separated on a Dowex-50
column (1.3 by 50 cm) by elution with 1.5 N HCl.
Thymidine, thymine, and 5-HMU were also distin-
guished by one-dimensional paper chromatography
(Whatman no. 1) by using the following three solvent
systems: water (100), ethyl acetate-formic acid-water
(70:20: 10), and t-butanol-methyl ethyl ketone-water-
concentrated NH4OH (40:30:20:10).
RESULTS
Mutant isolation and genetics. The mutant
selection procedures described yielded six classes
of mutants which were given the designation
uracil (uc) or uridine (ud). When a selection pro-
cedure yielded more than one mutant of a given
class, only one was chosen for further work. The
six representative mutants and their isolation
numbers are uc-i (RW-57), uc-2 (RW-135), uc-3
(RW-203), uc-4 (RW-341), uc-S (RW-399), and
ud-i (RW-433). Each mutant isolate was crossed
to wild type, and dissection of 10 to 20 ordered
asci was carried out for each cross. All asci were
consistent with a 2:2 segregation of the new muta-
tions among the spore pairs. Recombinants carry-
ing uc or ud mutations in an otherwise wild-type
background behaved as prototrophs. This is con-
sistent with the hypothesis that pyrimidine sal-
vage pathways are nonessential to growth. Segre-
gants carrying the new mutations were selected
from the crosses, and these were used in all further
studies.
The genetic map position of the six mutations
remains to be determined, but the following link-
age relationships are known: uc-i to pyr-4 on
chromosome II, uc-2 and uc-4 to mating type on
chromosome I, and uc-5 to pyr-i on chromosome
IV. Uc-3 and ud-i have not been assigned to a
linkage group. It is evident that the mutations
affecting pyrimidine salvage are not clustered on
the genetic map.
Characterization of mutants of the thymidine
salvage pathway. The uc-i mutation (obtained by
the second selection method) when introduced
into a pyr-4 strain allowed the utilization of thy-
midine, thymine, 5-HMU, and 5-formyluracil as
sole pyrimidine sources, whereas in the absence
of uc-i these compounds could only be used after
uridine or cytidine had initiated growth. (Table 1
shows sparing action of thymidine, thymine, and
5-HMU for uridine. Identical results are obtained
if cytidine replaces uridine.) Although the regula-
tory nature of the uc-i mutation in no way altered
the distribution of administered 2-14C-thymidine
or 2-_4C-thymine (90% of nucleic acid label in
RNA, 10% in DNA), the pyr-4 uc-i double mu-
tant was very useful as a parent strain for the
selection of mutants in which the thymidine deg-
radative pathway is blocked.
The uc-2 mutation (obtained by the first and
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third selection methods) allows all of the proposed
intermediates of the thymidine degradative path-
way to be used except the initial compound,
thymidine (Table 1). It is proposed that the uc-2
mutation blocks the first step of the pathway,
cleavage of the deoxyribose sugar from the thy-
mine moiety, through formation of a defective
nucleosidase enzyme. The nucleosidase is thought
to be specific for all pyrimidine deoxyribonucleo-
sides since, in contrast to the parent pyr-4 uc-l
strain, the pyr-4 uc-1 uc-2 mutant cannot utilize
deoxyuridine, deoxycytidine, or thymidine (Table
1). Further, the growth inhibition caused by a
TABLE 1. Growth response to several pyrimidines
by mutants of the pyrmidine salvage pathway
Dry weight of mycelial pad
Pyrimidine supplementa pyr-4Gy-
pyr-4 pyr-4 ucI u-
cc-i uc-2 uc-3
mg mg mg mg
Uridine............... 22 14 13 12
Uridine + thymidine.. 42 48 14 13
Uridine + thymine 39 45 39 13
Uridine+HMU. ......4548 35 13
Thymidine............ 0 22 0 0
Thymine.............. 0 21 19 0
5-HMU............... 0 21 22 0
5-Formyluracil. ............ 0 20 19 16
Uracil................ 17 16 17 16
Deoxyuridine ......... 20 14 2 17
Deoxycytidine ........ 6 13 0 17
Thymidine ........... 0 22 0 0
a Each supplement was added in the amount of
1.0 pmole per flask.
fourth pyrimidine deoxyribonucleoside, 5-fluoro-
deoxyuridine (5-FUdR), is of much longer dura-
tion in strains carrying uc-2 than in those lacking
it, indicating that uc-2 prevents the breakdown of
5-FUdR. The uc-2 mutation does not affect the
utilization of purine deoxyribonucleoside since
the growth of an ad-6 uc-2 mutant was good on
deoxyadenosine as a purine source.
When thymidine and uridine are administered
to a pyr-4 uc-2 double mutant, the majority of the
thymidine remains in the growth medium (Table
2). This is in contrast to the removal of all thymi-
dine from the medium that a pyr-4 mutant effects
under similar growth conditions.
The uc-3 mutation (obtained by the third selec-
tion method) prevents the utilization of the first
three proposed intermediates of the thymidine
degradative pathway, thymidine, thymine, and
5-HMU (Table 1). The fact that the use of 5-for-
myluracil and uracil is unhindered leads to the
conclusion that the uc-3 mutation causes a defec-
tive enzyme required in the 5-HMU to 5-formyl-
uracil conversion. That uc-3-carrying strains can
partially metabolize thymidine was made clear
when the used medium of a uc-3 mutant grown in
the presence of thymidine was found to support
the growth of a pyr-4 uc-l uc-2 triple mutant.
This accumulated product was found to be thy-
mine (Table 2). Wild type removes thymidine
from the medium as rapidly as does uc-3, but
excretes very little thymine. Curiously, no 5-HMU
was found in the used medium of uc-3 (nor in the
used medium of wild type) incubated with thymi-
dine. It should be reemphasized here that uc and
ud mutants grow well on minimal medium in the
absence of a pyr mutation. Since the uc-3 mutant
is a prototroph, the addition of uridine or cytidine
is not required to initiate the growth necessary
TABLE 2. Utilization and excretion of pyrimidines by uc mutantsa
Medium before growth Medium after growth
Mutant growth
Pyrimidine Amt Pyrimidine Amt
pimwles pmoles
pyr-4 Uridine + 14C-thymidine 1.0 each None 0 90
pyr-4 uc-2 Uridine + 14C-thymidine 1.0 each 14C-Thymidine 0.80 90
Wild type Thymidine 20 Thymine 1 120
Thymidine 5
uc-3 Thymidine 20 Thymine 11 120
Thymidine 5
Wild type Uridine 10 None 0 70
uc-4 Uridine 10 Uracil 5 70
a Pyrimidine supplements were in 25 ml of medium. Dry weights of mycelial pads were: pyr-4 38, mg;
pyr-4 uc-2, 20 mg; wild, uc-3 and uc-4, all 100 to 130 mg.
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for the functioning of the thymidine degradative
pathway.
The uc-4 mutation (obtained by the fourth
selection method) prevents the utilization of thy-
midine, thymine, 5-HMU, 5-formyluracil, and
uracil as pyrimidine sources for the pyr-J uc-4
mutant (Table 3). This is true even if growth is
initiated by small amounts of uridine. On the
basis of growth data, the uc-4 mutation can be
assigned to blocking a step involved in the con-
version of uracil to uridylic acid. The relatively
poor growth of the pyr-l uc-4 mutant on uridine
is explained by the fact that half of the uridine
administered is excreted into the medium as
uracil, which the mutant cannot use. A uc-4 mu-
tant given uridine accumulates uracil in the
medium, whereas wild type does not (Table 2).
Pyrimidine transport. The procedures used in
selection for mutants which could not utilize a
given pyrimidine could yield two types of mutants,
those defective in enzymes converting the pyrimi-
dine into nucleic acid and those lacking the ability
to transport the pyrimidine into the cell. The pro-
cedures used here have been used to isolate trans-
port mutants in bacteria (17). Growth data from
two double mutants pyr-l uc-S (fourth selection
method) and pyr-l ud-1 (fifth selection method)
suggest the simple interpretation that uc-5 and
ud-l disrupt pyrimidine transport mechanisms
(Table 4).
The pyr-J uc-S mutant is unable to utilize any
free pyrimidine base (thymine, 5-HMU, 5-for-
myluracil, and uracil), although it can use the
ribose and deoxyribose pyrimidine nucleosides
(cytidine, uridine, deoxyuridine, and thymidine)
in a normal manner. In an exactly reverse manner,
the pyr-1 ud-1 double mutant can use all of the
free bases but none of the pyrimidine nucleosides.
The hypothesis then is that the uc-S locus controls
a transport system for the free base pyrimidines
TABLE 3. Growth response to several pyrimidines
by pyr-J and pyr-l uc-4 mutants
Dry weight of mycelial pad
Pyrimidine supplement'
pyr-I pyr-l uc-4
mg mg
Uridineb........ 33 11
Uridine ................... 18 6
Uridine + thymidine ...... 32 6
Uridine + 5-HMU 32 6
Uridine + uracil 31 6
Uracil.................... 18 0
Unless otherwise indicated, each supplement was
added in the amount of 1.0,tmole per flask.
b Uridine supplement here was 2.0 Mmoles/flask.
TABLE 4. Effect of uc-5 and ud-l mutations on
utilization of pyrimidine nucleosides
and free bases
Dry weight (mg) of mycelial pad
Pyrimidine supplementa
pyr-l pyr-l ud-i pyr-l uc-5
Uridineb . . ........... 33 0 36
Cytidine ...... 18 0 21
Uridine ............... 18 0 21
Uridine + thymidine.. 32 0 38
Uridine + uracil...... 31 20 21
Uracil ................ 18 18 1
Uracil + thymidine 29 19 0
Uracil + thymine..... 29 31 0
aUnless otherwise indicated, each supplement was
added in the amount of 1.0,umole per flask.
b Uridine supplement here was 2.0 jsmoles/flask.
and the ud-l locus controls a system for pyrimi-
dine nucleosides. The unlinked uc-4 and uc-S
mutations cause similar growth responses to most
pyrimidines, but they can easily be distinguished
by growth on thymidine. The uc-4 strains (blocked
at the last step of thymidine degradative pathway)
cannot utilize thymidine, whereas uc-S strains use
the thymidine very efficiently.
"4C-pyrimidine incorporation. It has been
demonstrated that when Neurospora is grown in
the presence of 2-14C-thymidine and 2-_14C-thy-
mine, 90% of the resulting nucleic acid label is
recovered in the RNA fraction, and when 14Cl
methyl-labeled thymidine is administered no label
is found in either RNA or DNA (13, 14). These
facts alone do not prove that Neurospora cannot
phosphorylate thymidine and incorporate it di-
rectly in DNA. An alternate possibility is that
Neurospora may have a thymidine phosphorylat-
ing system of low activity which would not be
detected because of the rapid conversion of its
substrate, thymidine, to compounds which are
unavailable for specific incorporation in DNA.
To test this possibility, 2-_4C-thymidine and 2-14C-
thymine were separately administered to a
pyr-4 uc-2 double mutant; the uc-2 mutation, as
described previously, blocks the initial step in the
degradation of thymidine (Table 5). Both the
pyr-4 uc-J double mutant and a control pyr-4
strain convert 60 to 70% of the label originally
present as 2-14C-thymine into RNA constituents.
The pyr-4 mutant converts the label of 2-'4C-thy-
midine in a similar manner, but the pyr-4 uc-2
mutant transforms only 10% of the label to RNA,
whereas over 75% of the thymidine remains
unused in the growth medium. However, the
amount of label found in pyr-4 uc-2 DNA was
proportionately reduced and the distribution of
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TABLE 5. Distribution and utilization of 2-14C-
thymidine and 2-14C-thymine label by pyr-4 and
pyr-4 uc-2 mutants"
Per cent of initial label after 90
hr of growth
Solution counted pyr-4 pyr-4 uc-2
2-14C- 2-14C- 2-14C- 2-14C-
Thymi- Thy- Thymi- Thy-dine mine dine mine
Growth medium. 8 8 78 8
Alcohol-ether extracts 1 3 2 2
RNA extracts 73 60 10 69
DNA extracts 5 5 1 6
Per cent of total nu-
cleic acid counts due
to DNA.7 8 9 8
Per cent of total nu-
cleic acid that is
DNA.9 10 9 8
Flasks containing 25 ml of medium, 1.0 pmole
of uridine, and either 1.0 smole of thymidine
(S.A., 1.5 uc/p&mole) or 1.0 Amole of thymine (S.A.,
2.0 ,uc/,umole) were prepared. Pyr-4 and pyr-4 uc-i
conidia were inoculated into one flask of each
type, and growth was allowed for 90 hr at 25 C.
Extraction of the mycelial pads was accomplished
as described in Materials and Methods.
nucleic acid label remained approximately 90%
RNA and 10% DNA. Therefore, under condi-
tions in which the conversion of thymidine to
RNA precursors was largely blocked, no evidence
for the specific incorporation of thymidine into
DNA could be shown.
DISCUSSION
Figure 1 shows a pathway by which the pyrimi-
dine ring of thymidine can be converted to uridylic
acid and thus made available for incorporation
into RNA and DNA pyrimidines. The order of
intermediates in the pathway was based on nutri-
tional tests and accumulation studies with strains
carrying uc-2, uc-3, and uc-4 mutations. The hy-
pothesis that the uc-2 mutation causes formation
of a defective pyrimidine deoxyribonucleosidase
enzyme is similar to the explanation of an Fscher-
ichia coli mutant (11) which had lost the ability
to use thymidine, deoxyuridine, and deoxycyti-
dine as carbon sources. This mutant was shown to
lack thymidine phosphorylase activity, the en-
zyme responsible for the cleavage of the deoxy
sugar from thymidine.
The uc-3 mutation prevents the oxidation of
5-HMU to 5-formyluracil because uc-3-carrying
strains utilize the formyl compound but not 5-
HMU as a pyrimidine source. However, since a
uc-3 mutant administered thymidine accumulates
large quantities of thymine and none of the ex-
pected 5-HMU, the possibility exists that the
uc-3 locus may also control the thymine to 5-
HMU conversion. Abbott and co-workers (1, 2)
demonstrated the formation of 5-HMU from
thymine (thymine-7-hydroxylase) and of 5-for-
myluracil from 5-HMU by cell-free extracts of
Neurospora. The two enzyme activities which have
been only partially separated by initial purifica-
tion steps both require 02 and Fe++, a-ketoglu-
tarate, and ascorbate as cofactors. The uc-3 mu-
tant strain, whether it is found to lack one or
both of the two enzyme activities, should prove
quite useful in work on the enzymology of thy-
mine methyl group oxidation. From what is
known of uracil salvage enzymes in other micro-
organisms (8, 10), it is probable that the uc-4
mutation causes an inactive pyrophosphorylase
enzyme for the one-step formation of uridine-5'-
phosphate from uracil.
The classification of uc-l as a regulatory gene is
based on the fact that strains carrying this muta-
tion can use thymidine, thymine, 5-HMU, and
5-formyluracil as sole pyrimidine sources. These
growth responses are interpreted to mean that the
enzyme(s) necessary for the conversion of 5-for-
myluracil to uracil is derepressed (or is present
at normal levels but not subject to inhibition) in
germinating conidia of uc-l strains. The growth
tests provide no clue as to whether enzymatic
steps before 5-formyluracil in the pathway are
subject to control by the uc-1 gene.
Uracil-5-carboxylic acid (5-CU) could be pro-
posed as an intermediate of the thymidine degra-
dative pathway since it might easily be formed
from 5-formyluracil and yield uracil upon loss of
CO2. However, growth tests with pyr mutants
show this compound, in contrast to the other
intermediates, to be used very inefficiently as a
pyrimidine source. Furthermore, no mutants were
found which accumulated 5-CU, nor were mutant
hunts successful in finding strains which could
utilize the compound as a pyrimidine source. The
role of 5-CU as an intermediate awaits the study
of enzymes of the pathway.
The pathway for the conversion of thymidine
into an RNA precursor is undoubtedly present or
capable of being induced in a large number of
other organisms. The possibility of the presence
of this pathway should be considered in any ex-
periment in which thymidine is to be used for the
specific labeling of DNA.
Data were presented showing that 2-'4C-thy-
midine administered to a strain carrying the uc-2
mutation did not lead to an increased percentage
of label incorporated into the DNA. This sub-
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stantiates the hypothesis of Fink (13) that Neuro-
spora lacks a thymidine-phosphorylating enzyme.
Grivell and Jackson (15) have been unable to
demonstrate thymidine kinase (E.C. 2.7.1.21)
activity in Neurospora, Aspergillus, and Sac-
charomyces. Since a large portion of the thymidine
given to strains carrying uc-2 remains unused in
the medium, it can be assumed that conversion of
thymidine to thymine is the only reaction of sig-
nificance that thymidine can undergo in Neuro-
spora. The lack of a thymidine-phosphorylating
enzyme makes it quite doubtful that a thymidine
mutant (possessing a nonfunctioning thymidylate
synthetase enzyme and, therefore, dependent for
growth upon a secondary synthesis of thymidylic
acid) of Neurospora can be isolated.
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